LON:IMM

ImmuPharma (IMM) Share Forecast, Price & News

GBX 1.82

-0.08 (-4.31%)

(As of 04:25 PM ET)

Compare

Today's Range: 1.73
▼
1.92
50-Day Range: 1.81
▼
2.59
52-Week Range: 1.36
▼
4.10

Volume: 626,082 shs
Average Volume: 1.41 million shs
Market Capitalization: £7.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines

About ImmuPharma (LON:IMM) Stock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

IMM Price History

30 days | 90 days | 365 days | Advanced Chart

IMM Stock News Headlines

September 20, 2023 | americanbankingnews.com

ImmuPharma (LON:IMM) Stock Crosses Below 200 Day Moving Average of $2.47

August 31, 2023 | lse.co.uk

ImmuPharma launches GBP2 million fund raise as interim loss narrows

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

August 31, 2023 | marketwatch.com

ImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working Capital

August 21, 2023 | lse.co.uk

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

June 27, 2023 | proactiveinvestors.com

ImmuPharma "absolutely delighted" to push on with new clinical trial

June 19, 2023 | proactiveinvestors.com

ImmuPharma presses on with next phase of Lupuzor clinical trials

May 24, 2023 | proactiveinvestors.com

ImmuPharma "looking forward with quiet confidence" to FDA response

September 27, 2023 | Micro-Cap Stock Trader (Ad)

Windfall profits possible with this under-the-radar lithium stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

May 18, 2023 | uk.investing.com

FTSE 100 remains higher but off best with Wall Street indicated mixed

May 18, 2023 | marketwatch.com

ImmuPharma Shares Rise on Positive Guidance From US FDA for P140

May 18, 2023 | proactiveinvestors.com

ImmuPharma shares jump 6.5% after FDA update

May 18, 2023 | proactiveinvestors.com

ImmuPharma says CIDP trial will begin in the second half after meeting with US regulator

May 12, 2023 | marketwatch.com

Systemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029

May 11, 2023 | proactiveinvestors.com

ImmuPharama eyes clinical trial progress

May 11, 2023 | proactiveinvestors.com

ImmuPharma eyes clinical trial progress

April 27, 2023 | proactiveinvestors.com

ImmuPharma "looking forward" to upcoming FDA meetings

April 19, 2023 | proactiveinvestors.com

ImmuPharma partner gets FDA meeting date

April 12, 2023 | marketwatch.com

ImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical Program

April 12, 2023 | proactiveinvestors.com

ImmuPharma rises 4% after it reveals headway with lead asset

April 12, 2023 | proactiveinvestors.com

ImmuPharma makes progress developing second indication for lead asset

March 30, 2023 | marketwatch.com

Systemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031

March 27, 2023 | proactiveinvestors.com

ImmuPharma: US partner has submitted Lupuzor phase II/III trial protocol

March 27, 2023 | marketwatch.com

ImmuPharma Shares Rise on Lupus Candidate FDA Trial Submission

March 27, 2023 | proactiveinvestors.com

ImmuPharma: US partner submits Lupuzor phase II/III trial protocol

March 6, 2023 | proactiveinvestors.com

ImmuPharma collaborates on potential 'radioactive bullet' to kill cancer

February 14, 2023 | marketwatch.com

Cutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutions

See More Headlines

Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Company Calendar

Last Earnings: 9/30/2020
Today: 9/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:IMM
CUSIP: N/A
CIK: N/A
Web: www.immupharma.org
Phone: +44-20-71524080
Fax: N/A
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-2,990,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -159.35%
Return on Assets: -53.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.17
Quick Ratio: 1.03

Sales & Book Value

Annual Sales: £94,819.00
Price / Sales: 79.98
Cash Flow: GBX 0.09 per share
Price / Cash Flow: 20.50
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 416,440,000
Free Float: N/A
Market Cap: £7.58 million
Optionable: Not Optionable
Beta: 1.39

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Timothy Paul McCarthy XIV (Age 66)
FCCA, M.B.A., MBA, Chairman & CEO
Comp: $106.5k

Dr. Timothy Gary Franklin M.B.A.
Ph.D., COO & Director

Ms. Lisa Baderoon
Head of Investor Relations & Non Exec. Director

Dr. Jean-Marie Geiger PharmD
MD, Head of Clinical Devel.

Dr. Laura Mauran-Ambrosino
Chief Scientific Officer of ImmuPharma Biotech

Ms. Lara E. Sucheston-Campbell
Head of Clinical & Medical Affairs

Dr. Sébastien R. Goudreau Ph.D.
CEO of ImmuPharma Biotec & Director

Key Competitors

View All Competitors

IMM Stock - Frequently Asked Questions

How have IMM shares performed in 2023?: ImmuPharma's stock was trading at GBX 1.84 at the start of the year. Since then, IMM stock has decreased by 1.0% and is now trading at GBX 1.82.
View the best growth stocks for 2023 here.
How were ImmuPharma's earnings last quarter?: ImmuPharma plc (LON:IMM) released its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.
What other stocks do shareholders of ImmuPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).
What is ImmuPharma's stock symbol?: ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?: Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is ImmuPharma's stock price today?: One share of IMM stock can currently be purchased for approximately GBX 1.82.
How much money does ImmuPharma make?: ImmuPharma (LON:IMM) has a market capitalization of £7.58 million and generates £94,819.00 in revenue each year. The company earns £-2,990,000.00 in net income (profit) each year or GBX (0.01) on an earnings per share basis.
How can I contact ImmuPharma?: ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The official website for the company is www.immupharma.org. The company can be reached via phone at +44-20-71524080.

This page (LON:IMM) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial